securities class action

Law firm Levi & Korsinsky files class action against Inovio Pharmaceuticals for allegedly false statements regarding device manufacturing and FDA pathways from October 2023 to December 2025.

Snowflake faces securities fraud suit after 18% stock drop on corrective disclosures regarding consumption patterns and $10B revenue target claims.

Nektar Therapeutics faces securities lawsuit over REZOLVE-AA trial enrollment irregularities. Eligible investors have until May 5, 2026 to pursue compensation.

Class action lawsuit filed against $LAKE alleging false statements about Pacific Helmets and Jolly acquisitions. Investors with claims must act before April 24, 2026 deadline.

Rosen Law Firm urges Navan (NAVN) IPO investors to join securities lawsuit by April 24, 2026, alleging misleading offering documents and undisclosed expense increases.

Securities class action filed against uniQure alleging FDA approval misrepresentations. April 13, 2026 deadline for lead plaintiff claims.

Securities class action filed against $PYPL for allegedly making false statements about 2027 financial targets and Branded Checkout growth. April 20, 2026 deadline for lead plaintiff claims.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Law firm investigates Zynex securities fraud claims; investors face April 2026 deadline for federal class action lawsuit over alleged revenue inflation and Tricare payment fraud.

TruBridge disclosed material accounting errors in 2023-2025 financials, triggering a 10.5% stock decline and spurring shareholder litigation.

Boston Scientific faces class action over false electrophysiology segment statements. Investors from July 2025–February 2026 may recover damages; lead plaintiff deadline May 4, 2026.

$EOSE faces class action lawsuit over alleged false production capacity and performance claims. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against Aquestive Therapeutics over alleged false statements regarding Anaphylm drug application.

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.

Rosen Law Firm filed a class action lawsuit against Gartner ($IT) alleging false statements about growth targets. Lead plaintiff deadline is May 18, 2026.

Eos Energy Enterprises ($EOSE) faces securities lawsuit after missing revenue guidance by $35-46M, citing production issues. May 5, 2026 deadline for investor claims.

Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.

Picard Medical faces securities fraud lawsuit alleging false statements, social media manipulation, and insider share dumping scheme during September-October 2025 period.

Rosen Law Firm alerts Ramaco Resources investors of March 31, 2026 deadline to join securities lawsuit alleging false statements about Brook Mine operations.

$APO investors must act before May 1, 2026 deadline in securities lawsuit alleging executives falsely denied Epstein business relationship.